Given the current scale of censorship against anybody who challenges the 'accepted narrative' (epecially on Covid), the following updates aren't especially significant; but as these two emails landed in my inbox today within a few minutes of each other I thought it was worth sharing them.
First I got this email from Amazon.co.uk informing me that they were no longer able to 'source' the new book by genuine investigative reporter James O'Keefe exposing the corruption and lies of main stream media (despite the fact it is a best seller inthe US). This is despite the fact that I pre-ordered the book in October 2021.
We regret to inform you that we have been unable to source the following item:
O'Keefe, James "American Muckraker: Rethinking Journalism for the 21st Century"
Our supplier has informed us that this item is no longer available. This item has now been cancelled from your order #206-0106001-6090736. In case you have been charged for it, payment will be refunded within 5-7 business days.
We apologise for the length of time it has taken us to reach this conclusion. Until recently, we had still hoped to obtain this item for you.
Next I got I response from the Editor of one of the Frontiers journals after I had been asked to review material on Cybersecurity for a special issue of Frontiers in Computer Science. I had asked the following:
I have published in and reviewed for various Frontiers journals before but, before I consider investing any further effort with Frontiers, I would like a proper explanation for why Frontiers in Pharmacology pulled the special issue on repurposing existing drugs as COVID-19 treatments that Dr Robert Malone had worked on.
Here is the unhelpful and uninfomative response reponse I got back (for privacy reasons I am not including the name of the person who responded):
Thank you for your reply and your question.
I am the Journal Manager of Frontiers in Applied Mathematics and Statistics and Frontiers in Computer Science: my team and I work exclusively on these 2 journals. Therefore, regrettably, I am not familiar with nor able to provide any further details on a Frontiers in Pharmacology editorial project.
I hope this clarifies. Thank you for your time and attention on this matter, please don't hesitate to contact us again.